Dan Yao

Dr. Dan Yao


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2024 in Life Sciences
Verified
Journal Article
Open access
XLXiuchun Li
Xiuchun Li
YWYangyue Wang
Yangyue Wang
YCYuxin Chen
Yuxin Chen
ZLZiyi Lu
Ziyi Lu
YSYihan Sun
Yihan Sun
CYChang Yu
Chang Yu
Acute lung injury (ALI) is a life-threatening lung disease characterized by inflammatory cell infiltration and lung epithelial injury. Icariside II (ICS II), one of the main active ingredients of Herba Epimedii, exhibits anti-inflammatory and immunomodulatory effects. However, the effect and mechanism of ICS II in ALI remain unclear. The purpose of the current study was to investigate the pharmacological effect and underlying mechanism of ICS II in ALI. Models of neutrophil-like cells, human peripheral blood neutrophils, and lipopolysaccharide (LPS)-induced ALI mouse model were utilized. RT-qPCR and Western blotting determined the gene and protein expression levels. Protein distribution and quantification were analyzed by immunofluorescence. ICS II significantly reduced lung histopathological damage, edema, and inflammatory cell infiltration, and it reduced pro-inflammatory cytokines in ALI. There is an excessive activation of neutrophils leading to a significant production of NETs in ALI mice, a process mitigated by the administration of ICS II. In vivo and in vitro studies found that ICS II could decrease NET formation by targeting neutrophil C-X-C chemokine receptor type 4 (CXCR4). Further data showed that ICS II reduces the overproduction of dsDNA, a NETs-related component, thereby suppressing cGAS/STING/NF-κB signalling pathway activation and inflammatory mediators release in lung epithelial cells. This study suggested that ICS II may alleviate LPS-induced ALI by modulating the inflammatory response, indicating its potential as a therapeutic agent for ALI treatment.

20 June 2025 in Journal of Pharmaceutical Analysis
Verified
Journal Article
Open access
LSLanlan Song
Lanlan Song
CLChangyu Lei
Changyu Lei
CZCheng Zheng
Cheng Zheng
YLYichen Liu
Yichen Liu
JLJian Liu
Jian Liu
XHXiaoying Huang
Xiaoying Huang
Respiratory diseases pose a significant global health challenge due to their high morbidity and mortality rates. Traditional Chinese medicine (TCM), particularly the herb Epimedium, has demonstrated therapeutic potential in managing these diseases. This review systematically evaluates evidence from both in vitro and in vivo studies to assess the effects of Epimedium and its bioactive compounds, including icariin (ICA), icariside I (ICS I), icariside II (ICS II), icaritin (ICT), and others, on respiratory diseases. The synthesis of current literature reveals that these compounds exhibit anti-inflammatory, antioxidant, and immunomodulatory activities, as well as other effects crucial for the management of respiratory diseases. Further research is needed to fully understand and harness the therapeutic potential of Epimedium and its bioactive compounds in respiratory diseases.

14 April 2026 in The Journal of Pathology
Verified
Journal Article
Open access
LSLanlan Song
Lanlan Song
YLYichen Liu
Yichen Liu
CXChen Xu
Chen Xu
YZYaochen Zhang
Yaochen Zhang
KXKaiming Xu
Kaiming Xu
XHXiaoying Huang
Xiaoying Huang
Endoplasmic reticulum stress (ERS) occurs when the protein‐folding capacity of the endoplasmic reticulum (ER) is overwhelmed, triggering the unfolded protein response (UPR) to restore homeostasis. However, severe or persistent ERS can shift the UPR toward pro‐inflammatory, apoptotic, and fibrotic signaling, thereby exacerbating tissue injury. The pathogenesis and progression of lung diseases, which involve highly heterogeneous cell populations, are significantly influenced by these mechanisms. Indeed, ERS and UPR activation are now recognized as central players in the pathophysiology of numerous lung diseases. This review examines the impact of dysregulated ERS/UPR signaling across different lung diseases, with a particular focus on its cell‐type‐specific effects and disease‐specific implications. Furthermore, we discuss emerging therapeutic strategies designed to modulate these pathways. A comprehensive understanding of the cell‐type‐specific outcomes of ERS/UPR is therefore crucial for developing targeted interventions to mitigate or reverse lung disease progression. © 2026 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

26 May 2026 in BMC Cancer
Verified
Journal Article
Open access
PDF file
SZSisi Zheng
Sisi Zheng
ZZZiyi Zuo
Ziyi Zuo
RLRixu Lin
Rixu Lin
XZXiaoxiao Zhang
Xiaoxiao Zhang
LHLujie Huang
Lujie Huang
XHXiaoying Huang
Xiaoying Huang
Background: MET is a key driver in NSCLC yet comprehensive, multi-subtype real-world data in China are lacking. Methods: Real-world data were collected from MET-altered NSCLC patients diagnosed at a comprehensive hospital in southeastern China (July 2021–December 2023). Four subgroups were analyzed: MET IHC-Positive, MET Amplification, MET Exon 14 skipping, and MET Other Mutations. Demographics, risk factors, comorbidities, pathology, co-mutation, and treatment patterns were compared. With 2-year follow-up, survival outcomes and MET-TKI benefit were analyzed. Results: Among 574 patients: MET IHC-Pos (81.4%), MET-Amp (11.0%), MET-Ex14 (4.70%), and Others (2.96%). Patients were predominantly elderly, male, with > 40% smoking history and > 35% hypertension. Pathological specimens were mainly obtained via bronchoscopy or percutaneous lung puncture. Adenocarcinoma dominated all subtypes (> 70%), increasing with IHC intensity in MET IHC-Pos ( p < 0.05). MET-Amp showed the highest advanced stage (87.3%), bone (36.5%) and brain metastasis (17.5%). TP53 was the most common co-mutation (20.7%–25.0%). Targeted therapy predominated (Line 1st: 54.6%, Line 2nd: 38.9%), followed by chemotherapy plus immunotherapy. The 24-month OS was lower in MET-Amp (44.4%) and MET-Ex14 (48.1%) than in MET IHC-Pos (57.2%) and Others (58.8%). The 24-month OS (MET-TKI treated vs. untreated) was: 69.2% vs. 38.5% (MET IHC-Pos 2 + /3 +), 71.4% vs. 25.0% (MET-Ex14), and 47.4% vs. 42.9% (MET-Amp). Conclusions: MET alterations occur predominantly in the elderly, males, and smokers. MET-Ex14 shows driver-dependent characteristics with clear MET-TKI benefit. MET-Amp presents the most aggressive phenotype. MET IHC-Pos predominates (> 80%) with heterogeneity; the 2 + /3 + may benefit from MET-TKI. These findings inform subtype-based management of MET-altered NSCLC in southeastern China.

12 June 2026 in BMC Cancer
Verified
Journal Article
Open access
BXBeihui Xue
Beihui Xue
YLYichen Liu
Yichen Liu
MCMengsi Cai
Mengsi Cai
LGLiudan Gu
Liudan Gu
JBJiayu Bai
Jiayu Bai
DYDan Yao
Dan Yao
Accurate prediction of postoperative recurrence in lung adenocarcinoma (LUAD) is essential for guiding clinical decision-making and improving patient outcomes. Although various predictive models have been developed, most rely on complex genomic analyses and high-dimensional clinical data. The complexity of these approaches substantially limits their feasibility for routine clinical use. To address this clinical challenge, this study aims to predict postoperative recurrence using routinely available hematoxylin and eosin (H&E)-stained images and characterize the associated biological features. A total of 329 patients who underwent curative resection at the First Affiliated Hospital of Wenzhou Medical University (FHWMU) were retrospectively enrolled and randomly assigned to training and internal validation cohorts in a 7:3 ratio. An independent external validation cohort comprising 70 patients from the Clinical Proteomic Tumor Analysis Consortium (CPTAC) was included. Three patch-level feature extractors (Inception_V3, ResNet18, and DenseNet121) were evaluated within a weakly supervised multiple-instance learning (MIL) framework incorporating automated region-of-interest (ROI) detection on segmented whole-slide images (WSIs). Model performance was assessed using the area under the receiver operating characteristic curve (AUC), Kaplan-Meier (KM) survival analysis, and multivariable Cox proportional hazards regression. Transcriptomic profiling and gene set enrichment analysis (GSEA) were conducted to investigate biological differences between risk groups. The model achieved AUCs of 0.923 in the training cohort, 0.891 in the internal validation cohort, and 0.847 in the external validation cohort. The model effectively stratified patients into high- and low-risk groups with significantly different recurrence-free survival (RFS) across all cohorts (all P < 0.001) and retained prognostic value within AJCC stages I-III. Transcriptomic analyses revealed consistent enrichment of cell cycle-related pathways and neutrophil extracellular trap (NET) formation in high-risk patients across both institutional and CPTAC cohorts, aligning with distinct biological profiles of the model-derived risk stratification. This weakly supervised deep learning framework enables accurate and externally validated prediction of postoperative recurrence in LUAD using routinely available histopathological images, and integration of histopathological features with molecular analyses enhances biological interpretability. This work provides a clinically accessible and cost-effective tool for postoperative risk assessment in LUAD patients.

9 February 2026 in Cancers
Verified
Journal Article
Open access
PDF file
DYDan Yao
Dan Yao
YLYinting Liu
Yinting Liu
WYWenyao Yu
Wenyao Yu
SZSisi Zheng
Sisi Zheng
LHLujie Huang
Lujie Huang
XHXiaoying Huang
Xiaoying Huang
Background: SCLC remains an aggressive malignancy with limited therapeutic progress over the past few decades. It remains unclear how the sequence of immunotherapy initiation influences overall survival (OS) in SCLC; we performed a population-based analysis using NCDB to evaluate its association with survival. Methods: SCLC patients in NCDB from 2016 to 2021 were identified to evaluate the impact of immunotherapy on OS. Among ES-SCLC patients, we conducted subsequent analyses to clarify the relationship between the sequence of immunotherapy initiation and OS in the context of chemotherapy and CRT. Results: Among 69,820 eligible patients, 9242 received CRT plus immunotherapy (CRT + IO), and 11,755 received chemotherapy plus immunotherapy (Chemo + IO). In the overall population, adding immunotherapy to chemotherapy or CRT was associated with modestly improved survival. In ES-SCLC, immunotherapy was associated with longer survival in both the Chemo and CRT cohort, while the addition of immunotherapy did not confer benefits in limited-stage SCLC (LS-SCLC). Within the ES-SCLC Chemo + IO cohort, altering the initiated immunotherapy interval (0–90 days) did not show any meaningful difference in survival. By contrast, in the CRT + IO cohort, survival showed benefit in a time-dependent pattern: patients who initiated immunotherapy within 4–7 days after CRT had a trend of survival, which was consistent with the proposed immune activation window. Conclusions: This real-world analysis suggests that immunotherapy was associated with longer survival in ES-SCLC, CRT + IO is associated with improved OS, with a more obvious survival benefit when immunotherapy is initiated within 4–7 days after CRT. These findings hint at the potential importance of immunotherapy initiation sequence and warrant further prospective validation.